Holen Sie sich die Stockscreener-App
26.19
1.69%
-0.45
Handel nachbörslich:
26.19
Schlusskurs vom Vortag:
$26.64
Offen:
$26.86
24-Stunden-Volumen:
1.07M
Relative Volume:
1.50
Marktkapitalisierung:
$2.30B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-18.06
EPS:
-1.45
Netto-Cashflow:
$-134.36M
1W Leistung:
-18.11%
1M Leistung:
-14.24%
6M Leistung:
-35.33%
1J Leistung:
-13.76%
1-Tages-Spanne:
$25.62
$27.08
1-Wochen-Bereich:
$25.62
$32.00
52-Wochen-Spanne:
$25.62
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie IDYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IDYA | 26.19 | 2.30B | 23.38M | -155.22M | -134.36M | -1.45 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
Stephens Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences Names Chief Commercial Officer - Contract Pharma
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer - Marketscreener.com
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowTime to Sell? - MarketBeat
Ideaya Biosciences stock hits 52-week low at $27.51 By Investing.com - Investing.com Canada
Ideaya Biosciences stock hits 52-week low at $27.51 - Investing.com
Janus Henderson Group PLC's Strategic Acquisition in IDEAYA Bios - GuruFocus.com
IDEAYA Biosciences' SWOT analysis: biotech stock's potential in uveal melanoma treatment - Investing.com Australia
(IDYA) Investment Analysis - Stock Traders Daily
FMR LLC's Strategic Acquisition of IDEAYA Biosciences Inc Shares - GuruFocus.com
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise - 뉴스와이어
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - BioSpace
IDEAYA Biosciences to Present at Jefferies Conference, Host R&D Day in Late 2024 | IDYA Stock News - StockTitan
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - The Malaysian Reserve
Ideaya nominates B7H3/PTK7 bispecific ADC as development candidate - BioWorld Online
Fiera Capital Corp Sells 45,590 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Research Analysts Set Expectations for IDYA FY2024 Earnings - MarketBeat
90,000 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by General American Investors Co. Inc. - MarketBeat
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know - Yahoo Finance
The 3.2% return this week takes IDEAYA Biosciences' (NASDAQ:IDYA) shareholders five-year gains to 258% - Simply Wall St
Leerink Partnrs Issues Optimistic Estimate for IDYA Earnings - MarketBeat
FY2024 EPS Forecast for IDEAYA Biosciences Raised by Analyst - MarketBeat
Leerink Partnrs Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Hold - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 4.5%Here's Why - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to Market Perform at Leerink Partners - MarketBeat
IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) - Yahoo Finance
Wedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress - TipRanks
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
abrdn plc Buys Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowHere's What Happened - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Financial Times
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinic - GuruFocus.com
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline - MSN
IDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - The Malaysian Reserve
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase D - GuruFocus.com
WRN inhibitor IDE-275 gains IND clearance for phase I study in MSI-high tumors - BioWorld Online
IDEAYA Biosciences Reports Encouraging Clinical Data for IDE397 in MTAP-Deletion Urothelial Cancer and NSCLC - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $55.45 Average Price Target from Brokerages - MarketBeat
IDYAIDEAYA Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - Quantisnow
Leerink Partnrs Has Pessimistic View of IDYA Q3 Earnings - MarketBeat
UBS Group Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
Where are the Opportunities in (IDYA) - Stock Traders Daily
Analysts Offer Predictions for IDYA FY2024 Earnings - MarketBeat
Cantor Fitzgerald Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - Defense World
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):